loader
Please Wait
Applying Filters...

Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Approved Drug Products containing 209935 listed in the FDA Orange Book. Original Data : FDA Website

    Client Virtual Booth
    Menu

    Novartis Pharmaceuticals Corporation

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Send me more info on How To Grow My Business Digitally?

    Left Arrow
    Right Arrow
    Filters Filter
    Cross PopUp
    FILTER :

    filter

    01 NOVARTIS (1)

    filter

    01 TABLET;ORAL (1)

    filter

    01 RX (1)

    filter

    01 KISQALI FEMARA CO-PACK (COPACKAGED) (1)

    filter

    01 Yes (1)

    ListList of Suppliers
    refresh Reset Filter
    refresh Reset Filter
    product-page Supplier Virtual Booth
    price-trend Ask Us
    Contact Supplier
    • FDA
    • EDQM
    • WHO-GMP
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
    Post an Enquiry Post an Enquiry
    Flag Switzerland
    Virtual Booth Virtual Booth
    Digital Content Digital Content

    LETROZOLE; RIBOCICLIB SUCCINATE

    PDF Supplier PDF
    URL Supplier Web Content
    TABLET; ORAL
    2.5MG;EQ 200MG BAS...
    2017-05-04
    209935
    KISQALI FEMARA CO-...
    RX
    Yes
    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content

    Looking for FDA Orange Book APPLICATION 209935

    Looking for FDA Orange Book APPLICATION 209935 1

    19

    Novartis Pharmaceuticals Corporation, based in Switzerland, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.

    One of their notable products is LETROZOLE; RIBOCICLIB SUCCINATE, with a corresponding application number 209935.

    Regulatory Information RX

    With a dosage strength 2.5MG;EQ 200MG BASE

    Dosage Form Route TABLET; ORAL

    Reference Listed Drug Yes

    Approved since 2017-05-04

    Post Enquiry
    POST ENQUIRY